With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) ...
The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
Clinical Trials Arena on MSN
Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC
"Kelun-Biotech’s ADC plus Keytruda touts first-line success in late-stage NSCLC" was originally created and published by ...
Drug approvals this year have reflected the trend in clinical development of biologics shifting from intravenous to ...
– The First Pivotal Phase 3 Trial to Demonstrate Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care Keytruda plus Chemotherapy in 1L mTNBC – – Trodelvy ...
This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in one minute.
In November 2025, the U.S. Food and Drug Administration (FDA) issued several approvals across oncology and supportive care.
Five-year exploratory follow-up analysis of KEYNOTE-671 continued to show clinically meaningful improvements in overall survival and event-free survival with KEYTRUDA plus chemotherapy before surgery, ...
Keytruda and Padcev improve event-free and overall survival for adults with muscle invasive bladder cancer who cannot receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback